Growth Metrics

Eli Lilly (LLY) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $5.6 billion.

  • Eli Lilly's Income from Continuing Operations rose 47533.75% to $5.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 billion, marking a year-over-year increase of 11997.99%. This contributed to the annual value of $10.6 billion for FY2024, which is 10208.38% up from last year.
  • As of Q3 2025, Eli Lilly's Income from Continuing Operations stood at $5.6 billion, which was up 47533.75% from $5.7 billion recorded in Q2 2025.
  • In the past 5 years, Eli Lilly's Income from Continuing Operations registered a high of $5.7 billion during Q2 2025, and its lowest value of -$57.4 million during Q3 2023.
  • In the last 5 years, Eli Lilly's Income from Continuing Operations had a median value of $1.8 billion in 2023 and averaged $2.2 billion.
  • Per our database at Business Quant, Eli Lilly's Income from Continuing Operations crashed by 10395.4% in 2023 and then skyrocketed by 179041.81% in 2024.
  • Quarter analysis of 5 years shows Eli Lilly's Income from Continuing Operations stood at $1.7 billion in 2021, then increased by 12.26% to $1.9 billion in 2022, then grew by 13.01% to $2.2 billion in 2023, then surged by 101.39% to $4.4 billion in 2024, then rose by 26.59% to $5.6 billion in 2025.
  • Its Income from Continuing Operations stands at $5.6 billion for Q3 2025, versus $5.7 billion for Q2 2025 and $2.8 billion for Q1 2025.